Navigation Links
WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities
Date:12/17/2009

Partnership will develop proprietary medical food, functional food, and dietary supplement products with strong scientific roots and clinical support for burgeoning markets

North Brunswick, NJ and Blauvelt, NY (PRWEB) December 17, 2009 -- WellGen, Inc., a biotechnology company at the crossroads of foods and pharmaceuticals, and RFI Ingredients, a manufacturer of innovative natural ingredients, are pleased to announce the signing of a Memorandum of Understanding (MOU) covering a range of areas for cooperation. The new partnership is designed to enhance the business of both companies and bring exciting new natural products to the market. Products will have a strong base in science, solid clinical support, and affirmed GRAS (generally recognized as safe) status.
The MOU serves as a framework for collaboration on several high-growth opportunities: the creation of new medical foods for people with inflammation-related diseases for which there are major unmet needs; the creation of new dietary supplement and functional food products for consumer and health care professional markets; and the development and supply of natural ingredients with strong scientific and clinical support.

Commenting on the new relationship, Dr. Roddy Carter, president and chief executive officer of WellGen, states “the complementary skills of WellGen and RFI Ingredients will work synergistically to enhance the companies’ natural product offerings. Both companies have been acknowledged for their innovation and share a common interest in developing proprietary, high-quality products supported by strong clinical evidence. This collaboration will couple WellGen’s scientific and clinical know-how with RFI’s infrastructure and expertise in the natural products market. “

WellGen uses proprietary biotechnology methods and a deep understanding of natural products chemistry to develop and distinguish natural materials which they market in products for therapeutic purposes. WellGen is focused on inflammation-related disease for their medical food products and is currently working on a new medical food for diabetes.

RFI Ingredients, a manufacturer of natural ingredients has created a supply chain model and infrastructure that focuses on vertical integration and enhanced control over raw materials. RFI has an excellent track record in the development and marketing of branded ingredients. They have broad capabilities in ingredient supply and several proprietary ingredients in their portfolio of products. While RFI’s core business is ingredient supply, they also have two consumer brands, SoTru and PhytoRich.

“The proprietary research that WellGen has been conducting over the past four years combined with RFI’s innovative ingredients and superior approach to sourcing will provide a significant competitive advantage for both companies as we pursue parallel market opportunities.” stated RFI chief executive officer/ president and founder Jeff Wuagneux.

About RFI Ingredients
RFI Ingredients is a vertically-integrated manufacturer of innovative natural ingredients for the food, functional food and dietary supplement industries. The company, which was formed in 1989, specializes in the supply of quality ingredients (including certified-organic) and proprietary formulations. For more information about RFI Ingredients, please see www.RFIingredients.com.

About WellGen, Inc.
WellGen, Inc., based in North Brunswick, N.J., is a biotechnology company at the crossroads of foods and pharmaceuticals. Using the science of nutrigenomics, the company has developed Alignomx™, a proprietary bioinformatics model that uses gene expression data to determine optimal therapeutic areas for WellGen’s pipeline of proprietary natural products. Through its in-house expertise in nutrigenomics and natural product chemistry, WellGen is developing proprietary medical foods and has additionally identified several opportunities in the functional food and beverage and dietary supplement markets. For more information about WellGen, Inc., please see www.WellGen.com.

# # #

Read the full story at http://www.prweb.com/releases/2009/12/prweb3356744.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
2. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
3. Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc.
4. WellGen, Inc. Launches Te Ame(TM) Nutritional Supplements With Proven Health Benefits of Proprietary Black Tea Extract
5. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
6. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
7. Quantum dots and nanomaterials: Ingredients for better lighting and more reliable power
8. Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients
9. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
10. Ajinomoto Food Ingredients LLC Expands Capabilities
11. InVitrias Better Ingredients for Better Media to be Showcased at BPI 09
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 
(Date:2/24/2017)... SAN DIEGO , Feb. 24, 2017  Aethlon ... the following note authored by its Chairman and CEO, ... address at the Munich Security Conference last Saturday, ... engineered virus could kill more people than nuclear weapons. ... by U.S. and U.K. intelligence agencies, that scientific terrorists ...
(Date:2/24/2017)... Staten Island, NY (PRWEB) , ... February 24, 2017 , ... ... exponential rate. Founded in late 2014, FireflySci had the goal of bringing their ... 2017, that goal continues to shape the path that FireflySci is going on as ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
Breaking Biology News(10 mins):